Not all plasma cells are made equal: well-hidden layers of heterogeneity - Scorecard - MDSpire

Not all plasma cells are made equal: well-hidden layers of heterogeneity

  • By

  • Audrey Anoh Akessé

  • Amélie Bonaud

  • May 11, 2026

  • 0 min

Share

Clinical Scorecard: The Diverse Nature of Plasma Cells: Uncovering Hidden Layers of Heterogeneity

At a Glance

CategoryDetail
ConditionPlasma Cell Heterogeneity
Key MechanismsInfluenced by B cell lineage, antigen affinity, BCR signaling, tissue microenvironments, cytokines, and temporal factors.
Target PopulationIndividuals with varying immune responses, including those with autoimmune conditions, immunodeficiencies, and plasma cell malignancies.
Care SettingClinical research and immunology laboratories.

Key Highlights

  • Plasma cells are heterogeneous, with diverse origins and functions.
  • Long-lived plasma cells can persist outside the bone marrow.
  • Heterogeneity is shaped by intrinsic and extrinsic factors.
  • Distinct plasma cell subsets exhibit variations in phenotype and function.
  • Recent methodologies reveal significant molecular differences among plasma cells.

Guideline-Based Recommendations

Diagnosis

  • Utilize high-throughput and single-cell methodologies for assessing plasma cell populations.

Management

  • Consider the implications of plasma cell heterogeneity in vaccine formulation and immune modulation strategies.

Monitoring & Follow-up

  • Monitor plasma cell activity and longevity in patients with autoimmune diseases and malignancies.

Risks

  • Disruptions in plasma cell development can lead to autoimmune conditions and malignancies.

Patient & Prescribing Data

Patients with immune-related disorders and plasma cell malignancies.

Understanding plasma cell heterogeneity can inform targeted therapies and vaccine strategies.

Clinical Best Practices

  • Incorporate assessments of plasma cell diversity in clinical evaluations.
  • Tailor immunotherapy approaches based on plasma cell subtype characteristics.

References

Original Source(s)

Not all plasma cells are made equal: well-hidden layers of heterogeneity

  • by Audrey Anoh Akessé, Amélie Bonaud

  • May 11, 2026

Related Content

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders

Dana-Farber Team Develops Open-Access Predictive Tool to Improve Monitoring of Smoldering Multiple Myeloma

The tool, called PANGEA-SMM, outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment. The free online tool can be used immediately to monitor patients.

  • by

  • March 24, 2026

  • 5 min
This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min